相关临床试验
88
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1958
已完成
50
56.8%
暂无批准数据
- Hinge Bio has entered a collaboration and license agreement with Kyorin Pharmaceutical for HB2198 development in Japan, receiving $10 million upfront with potential milestone payments up to $95 million for SLE indication. - HB2198 is a multispecific antibody targeting both CD19 and CD20 with enhanced natural killer cell engagement, designed to achieve rapid and deep B cell depletion exceeding 99% in preclinical studies. - The therapeutic candidate is expected to enter clinical development in the second half of 2025, initially targeting systemic lupus erythematosus with plans to expand to other B cell-mediated autoimmune disorders. - Preclinical studies have demonstrated deeper and more rapid B cell depletion compared to other antibody-based therapies, positioning HB2198 as a potential immune system reset treatment.
- Eisai Thailand has launched Beova® Tablets (vibegron), a selective β3-adrenergic receptor agonist for overactive bladder treatment, marking the first market entry in Eisai's licensed ASEAN region. - The once-daily oral medication targets β3 receptors in the bladder to improve symptoms of urgency, frequent urination, and urge incontinence in patients with overactive bladder. - With overactive bladder affecting 15.8% of Thailand's population, the launch provides a new treatment option alongside Eisai's existing Uritos® tablets for addressing this condition that significantly impacts quality of life. - Approvals have also been obtained in the Philippines and Malaysia, with market preparations underway for these territories following the successful Thailand launch.
• A newly released global clinical trials review provides extensive data on Interstitial Cystitis research, tracking trial numbers and enrollment trends across major countries worldwide. • The report categorizes trials by region, phase, status, and sponsorship, highlighting key pharmaceutical companies including Astellas Pharma, AbbVie, Johnson & Johnson, and Pfizer as prominent sponsors. • This comprehensive analysis serves as a strategic resource for stakeholders making investment decisions in IC research, offering insights into trial success rates and identifying optimal locations for clinical studies.
